Amvuttra (vutrisiran) for transthyretin-mediated amyloidosis
Cigna coverage policy for prior authorization and medical necessity of Amvuttra (vutrisiran) for treatment of hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR polyneuropathy) and transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) in adults.
Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM) condition and criteria for approval were added to the policy.
Polyneuropathy criteria updated to require documentation that a transthyretin pathogenic variant is confirmed by genetic testing and documentation of symptomatic polyneuropathy.
Dosing updated to specify the dose is administered not more frequently than once every 3 months.
Removed requirement for documentation that other causes of neuropathy have been excluded (for example, diabetes).
Conditions Not Covered section updated to list concurrent use with other labeled therapies for hATTR or ATTR-CM (specific product list updated).
Documentation requirement added to policy indicating what documentation may include (chart notes, labs, genetic test results, etc.).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.